期刊文献+

三阴性乳腺癌的临床病理特征及化疗疗效分析

下载PDF
导出
摘要 目的:探讨三阴性乳腺癌患者的临床病理特征及预后影响因素,了解其化疗方案疗效。方法:收集免疫组化检测三阴性的106例患者临床病理资料,观察其生存情况。观察其化疗方案分布并回顾分析其疗效。结果:中位发病年龄53.7岁。单因素生存分析结果显示:术后未转移淋巴结数量,分期及术后辅助化疗方案与TNBC生存有关。辅助治疗中,含紫杉类方案与蒽环类方案相比,5a生存率94.7%和76.0%。复发转移患者最常使用的化疗方案依次为紫杉类76.9%,含铂方案46.2%,含吉西他滨方案42.3%。接受含铂方案化疗患者与未接受含铂方案患者中位生存时间(MS)分别为36.0个月和21.6个月,差异有统计学意义。结论:TNBC在我国的发病情况与文献报道相当。术后未转移淋巴结个数与TNBC预后相关。辅助治疗中,紫杉类方案优于其他方案。姑息治疗中,含铂方案可延长生存。值得进一步进行前瞻性研究。
出处 《临床医药实践》 2009年第11Z期2155-2157,共3页 Proceeding of Clinical Medicine
  • 相关文献

参考文献8

  • 1Rody A,Karn T,Solbach C,et al.The erbB2+cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel,doxorubicin and cyclophosphamide within the gepartrio trial[].Beast.2007
  • 2Rugo HS,Thomas ES,Lee RK,et al.Combination therapy with the novel epothilone B analog,ixabepilone,plus capecit-abine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes[].Breast Cancer Research.2007
  • 3Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[].Clinical Cancer Research.2004
  • 4Kennedy RD,Quinn JE,Mullan PB,et al.The role of BRCA1 in the cellular response to chemotherapy[].Journal of the National Cancer Institute.2004
  • 5Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of human breast tumours[].Nature.2000
  • 6Carlson RW,Moench SJ,Hammond ME,et al.HER2 testing in breast cancer:NCCN Task Force report and recommendations[].J Natl Compr Cane Netw.2006
  • 7C Fan,D Oh,L Wessels.Concordance among gene-expression-based predictors for breast cancer[].The New England Journal of Medicine.2006
  • 8Demeter,J,Deng,S,Geisler,S.Repeated observation of breast tumor subtypes in independent gene expression data sets[].Proceedings of the National Academy of Sciences of the United States of America.2003

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部